Veterinary Biologics Industry to Witness 7.7% Growth, Reaching $18.38 Billion by 2029
The veterinary biologics market size is expected to see strong growth in the next few years. It will grow to $18.38 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to emerging infectious diseases, climate change and disease patterns, precision livestock farming, one health approach, and increased pet ownership trends. Major trends in the forecast period include education and training programs, eco-friendly and sustainable biologics, integration of digital health records, rise in companion animal biologics, and customized and targeted therapies.
Get Your Free Sample of The Global Veterinary Biologics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12366&type=smp
Which Market drivers have played a significant role in driving the veterinary biologics market?
The rise in the prevalence of animal diseases is expected to propel the growth of the veterinary biologics market. Animal diseases refer to illnesses or health conditions affecting various animal species. Increasing animal diseases increase the need for better diagnosis and treatment, which can be achieved using veterinary biologics, which use immunological methods to treat animal diseases. For instance, in October 2022, according to the European Center for Disease Prevention and Control, a Sweden-based health agency of the European Union, a total of 2,467 avian influenza outbreaks in poultry, affecting 48 million birds, were recorded. 187 cases were detected in captive birds. Furthermore, in July 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, rabies kills 59,000 people annually in over 150 nations, with 95% of cases occurring in Africa and Asia. Therefore, the increasing cases of animal diseases are driving veterinary biologics.
What are the key segments within the veterinary biologics market?
The veterinary biologics market covered in this report is segmented –
1) By Product: Vaccines, Diagnostic Kits, Immunomodulators, Antiserums And Antibodies, Other Products
2) By Disease Type: Bluetongue, Foot And Mouth Disease, Brucellosis And Tuberculosis, Other Diseases
3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Other Distribution Channels
4) By Application: Production Animal, Companion Animal
Subsegments:
1) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, DNA Vaccines
2) By Diagnostic Kits: Rapid Tests, Elisa Kits, Pcr-Based Diagnostic Kits
3) By Immunomodulators: Cytokines, Adjuvants, Immunostimulants
4) By Antiserums And Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Hyperimmune Serums
5) By Other Products: Probiotics, Prebiotics, Growth Factors, Toxoids
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/veterinary-biologics-global-market-report
Which key players are shaping the veterinary biologics market?
Major companies operating in the veterinary biologics market include Bayer AG, Eli Lilly & Company, Evonik Industries AG, Zoetis Inc., Merck Animal Health Inc., Boehringer Ingelheim Animal Health Inc., Elanco Animal Health, IDEXX Laboratories Inc., Virbac SA, Phibro Animal Health Corporation, Vetoquinol, Abaxis Inc., Bimeda Biologicals, Ceva Sante Animale S.A., Heska Corporation, Colorado Serum Company, Hester Biosciences Limited, INDICAL Bioscience GmbH, Ambrx Biopharma Inc., Adamis Pharmaceuticals Corporation, Intervet Inc., Hebei Veyong Animal Pharmaceutical Co. Ltd., FidoCure, Biomet Biologics LLC, CytoDyn Veterinary Medicine LLC, KM Biologics
Which transformative trends will shape the veterinary biologics market landscape?
Major companies operating in the veterinary biologics market are focusing on developing novel biologics such as vaccines to enhance animal health and disease prevention. A vaccine is a substance that stimulates the immune system to recognize and fight specific pathogens. It helps prevent infectious diseases by providing acquired immunity. For instance, in August 2024, Merck Animal Health, a US-based global animal health company, launched an experimental autogenous vaccine targeting avian metapneumovirus (aMPV) type B, receiving approval from the U.S. Department of Agriculture (USDA) for manufacturing and sale. Developed in collaboration with Cambridge Technologies, this vaccine aims to combat the severe respiratory issues caused by aMPV type B in poultry, which have led to significant economic losses since late 2023. Produced at a state-of-the-art facility in Minnesota, the vaccine features an oil and water emulsion formulation designed to minimize post-vaccination tissue reactions, addressing a critical gap in the market as no commercially licensed vaccines were previously available.
How do regional factors impact the veterinary biologics market, and which region is the largest contributor?
North America was the largest region in the veterinary biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Veterinary Biologics Market Report 2025 Offer?
The veterinary biologics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Veterinary biologics refers to biological products derived from living organisms, such as bacteria, viruses, or other microorganisms. Veterinary biologics are used in veterinary medicine to prevent, diagnose, or treat animal diseases.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12366
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Comments
Post a Comment